Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Restructuring Costs: 2022-2024

Historic Restructuring Costs for Krystal Biotech (KRYS) over the last 1 years, with Sep 2024 value amounting to $12.5 million.

  • Krystal Biotech's Restructuring Costs was N/A to $12.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $50.0 million, marking a year-over-year change of. This contributed to the annual value of $37.5 million for FY2024, which is 200.00% up from last year.
  • Per Krystal Biotech's latest filing, its Restructuring Costs stood at $12.5 million for Q3 2024, which was down 0.00% from $12.5 million recorded in Q2 2024.
  • Krystal Biotech's Restructuring Costs' 5-year high stood at $25.0 million during Q1 2022, with a 5-year trough of $12.5 million in Q1 2023.
  • Its 3-year average for Restructuring Costs is $15.0 million, with a median of $12.5 million in 2024.
  • Data for Krystal Biotech's Restructuring Costs shows a maximum YoY plummeted of 50.00% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Krystal Biotech's Restructuring Costs stood at $25.0 million in 2022, then slumped by 50.00% to $12.5 million in 2023, then remained steady at $12.5 million in 2024.
  • Its Restructuring Costs was $12.5 million in Q3 2024, compared to $12.5 million in Q2 2024 and $12.5 million in Q1 2024.